home
company
science & technology
news & media
contact us
management
board of directors
scientific advisors
Company
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006. Michael Harpold, Ph.D., and Tom Reed, MBA, both previously with SIBIA Neurosciences, are also co-founders and provide valuable input on corporate matters. CalciMedica has acquired exclusive rights to both STIM1 and Orai1 to pursue the discovery of novel CRAC channel inhibitors for treating autoimmune diseases and organ transplant rejection.
 
Company
CalciMedica received its initial financing from SR One in December 2006 and closed Series A in July 2007. Series B was led by Sanderling Ventures, with participation from SR One, and closed in August 2007. Series C round was led by Biogen Idec New Ventures, with participation from Sanderling Ventures and SR One, and closed in November 2008.
 

 

 

 

 

 


HOME | COMPANY | SCIENCE & TECHNOLOGY | NEWS & MEDIA | CONTACT US | SITE MAP | TERMS OF USE
© Copyright 2014 - CalciMedica